Trio of approvals includes Seattle Genetics’ breast cancer therapy
Incyte’s Pemazyre pemigatinib approved for cholangiocarcinoma; Everest gains first approval via Singapore
Just two months after granting Priority Review to Seattle Genetics’ Tukysa tucatinib, FDA approved the drug as part of a triple combo to treat breast cancer, marking one of a trio of approvals Friday.
Incyte and Everest also announced approvals. ...
BCIQ Target Profiles
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)